<DOC>
	<DOC>NCT01300052</DOC>
	<brief_summary>The purpose of this study is to determine whether AN2728 topical ointment is a safe and effective treatment for mild-to-moderate plaque-type psoriasis.</brief_summary>
	<brief_title>AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Clinical diagnosis of stable mildtomoderate plaquetype psoriasis involving 235% of total body surface area (BSA) excluding face, scalp, and genitals Willingness and ability to apply study medication as directed, comply with study instructions, and commit to attending all study visits Women of childbearing potential must agree to use contraception for the entire study period Any dermatological conditions that could interfere with clinical evaluations Concurrent or recent use of certain topical or systemic medications without a sufficient washout period Significant confounding conditions as assessed by study doctor Participated in any other trial of an investigational drug within 30 days or participation in a research study concurrent with this study Use of lithium or hydroxychloroquinecontaining products (e.g., Plaquenil) Use of a betablocking medication (e.g., propranolol) if the dose has not been stabilized for at least 3 months Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>psoriasis</keyword>
</DOC>